Starry(SH:603520) Xin Lang Cai Jing·2025-10-30 10:20Core Insights - The company reported a revenue of 1.845 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 2.24% [1] - The net profit attributable to shareholders reached 28.82 million yuan, showing a significant increase of 221.14% year-on-year [1] - The basic earnings per share (EPS) stood at 0.07 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 21.83%, an increase of 0.39 percentage points year-on-year [2] - The net profit margin was 1.58%, up 1.07 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin improved to 27.37%, a year-on-year increase of 6.08 percentage points [2] - The net profit margin for Q3 was -0.07%, which is an increase of 2.87 percentage points year-on-year but a decrease of 2.20 percentage points quarter-on-quarter [2] Expense Management - Total operating expenses for Q3 2025 were 333 million yuan, a decrease of 24.04 million yuan year-on-year [2] - The expense ratio was 18.06%, down 1.74 percentage points from the previous year [2] - Sales expenses increased by 8.68%, while management expenses rose by 0.70%. R&D expenses decreased by 6.73%, and financial expenses saw a significant reduction of 36.27% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 32,600, a decrease of 1,102 from the end of the previous half-year, representing a decline of 3.27% [2] - The average market value per shareholder increased from 127,400 yuan to 146,300 yuan, reflecting a growth of 14.88% [2] Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [3] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [3] - The revenue composition includes 79.73% from contrast agents, 10.19% from other supplementary products, 6.16% from other sources, 2.41% from CMO/CDMO, and 1.52% from quinolone series [3] - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and raw materials [3]